Multiple System Atrophy - Pipeline Review, H1 2017

  • ID: 4311805
  • Drug Pipelines
  • 33 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AFFiRiS AG
  • Corestem Inc
  • Neuropore Therapies Inc
  • Prana Biotechnology Ltd
  • MORE
Multiple System Atrophy - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Multiple System Atrophy - Pipeline Review, H1 2017, provides an overview of the Multiple System Atrophy (Central Nervous System) pipeline landscape.

Multiple system atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs body's involuntary functions (blood pressure, heart rate, bladder function and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson's medications.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Multiple System Atrophy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Multiple System Atrophy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple System Atrophy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 3 and 1 respectively.

Multiple System Atrophy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple System Atrophy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Multiple System Atrophy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Multiple System Atrophy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Multiple System Atrophy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Multiple System Atrophy (Central Nervous System)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Multiple System Atrophy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Multiple System Atrophy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AFFiRiS AG
  • Corestem Inc
  • Neuropore Therapies Inc
  • Prana Biotechnology Ltd
  • MORE
  1. Introduction
  2. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Overview
  3. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Companies Involved in Therapeutics Development
  13. AFFiRiS AG
  14. Corestem Inc
  15. Neuropore Therapies Inc
  16. Prana Biotechnology Ltd
  17. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Drug Profiles
  18. Anle-138b - Drug Profile
  19. Product Description
  20. Mechanism Of Action
  21. R&D Progress
  22. CS-10BR05 - Drug Profile
  23. Product Description
  24. Mechanism Of Action
  25. R&D Progress
  26. ENT-01 - Drug Profile
  27. Product Description
  28. Mechanism Of Action
  29. R&D Progress
  30. NPT-20011 - Drug Profile
  31. Product Description
  32. Mechanism Of Action
  33. R&D Progress
  34. PBT-434 - Drug Profile
  35. Product Description
  36. Mechanism Of Action
  37. R&D Progress
  38. PD-01 - Drug Profile
  39. Product Description
  40. Mechanism Of Action
  41. R&D Progress
  42. PD-03 - Drug Profile
  43. Product Description
  44. Mechanism Of Action
  45. R&D Progress
  46. Small Molecules for Neurodegenerative Disease - Drug Profile
  47. Product Description
  48. Mechanism Of Action
  49. R&D Progress
  50. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Discontinued Products
  51. Appendix
  52. Methodology
  53. Coverage
  54. Secondary Research
  55. Primary Research
  56. Expert Panel Validation
  57. Contact Us
  58. Disclaimer
List of Tables:
  1. Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H1
  2. Number of Products under Development by Companies, H1
  3. Products under Development by Companies, H1
  4. Number of Products by Stage and Target, H1
  5. Number of Products by Stage and Mechanism of Action, H1
  6. Number of Products by Stage and Route of Administration, H1
  7. Number of Products by Stage and Molecule Type, H1
  8. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by AFFiRiS AG, H1
  9. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Corestem Inc, H1
  10. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Neuropore Therapies Inc, H1
  11. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Prana Biotechnology Ltd, H1
  12. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Discontinued Products, H1
List of Figures:
  1. Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products by Stage and Targets, H1
  4. Number of Products by Stage and Mechanism of Actions, H1
  5. Number of Products by Routes of Administration, H1
  6. Number of Products by Stage and Routes of Administration, H1
  7. Number of Products by Molecule Types, H1
  8. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AFFiRiS AG
  • Corestem Inc
  • Neuropore Therapies Inc
  • Prana Biotechnology Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll